Introduction
Patients and methods
Study design
Treatment protocol
Follow-up
Statistical analysis
Results
Patient characteristics
characteristics | Original data set | Matched data set | ||||||
---|---|---|---|---|---|---|---|---|
Men(%) | Women(%) | χ2 /t | p | Men(%) | Women(%) | χ2 /t | p | |
Age (years) | 63 (39–89) | 68 (40–95) | −3.49 | 0.001 | 65.5 (43–89) | 67 (40–95) | −1.525 | 0.128 |
Location | 3.27 | 0.352 | 2.54 | 0.468 | ||||
Cervical | 31 (6.2) | 14 (7.5) | 17 (9.6) | 12 (6.7) | ||||
Upper thoracic | 106 (21.3) | 45 (24.2) | 46 (25.8) | 41 (23.0) | ||||
Middle thoracic | 291 (58.6) | 110 (59.1) | 92 (52.8) | 108 (60.7) | ||||
Lower thoracic | 69 (13.9) | 17 (9.1) | 21 (11.8) | 17 (9.6) | ||||
T stage | 12.11 | 0.007 | 2.14 | 0.543 | ||||
T1 | 8 (1.6) | 6 (3.2) | 5 (2.8) | 4 (2.2) | ||||
T2 | 12,024.1) | 65 (34.9) | 51 (28.7) | 62 (34.8) | ||||
T3 | 135 (27.2) | 50 (26.9) | 57 (32.0) | 47 (26.4) | ||||
T4 | 234 (47.1) | 65 (34.9) | 65 (36.5) | 65 (36.5) | ||||
N stage | 12.51 | 0.000 | 0.354 | 0.552 | ||||
N0 | 88 (17.7) | 56 (30.9) | 46 (25.8) | 51 (28.7) | ||||
N1 | 409 (82.3) | 130 (69.1) | 132 (74.2) | 127 (71.3) | ||||
TNM stage | 17.70 | 0.001 | 4.35 | 0.226 | ||||
I | 47 (9.5) | 36 (19.4) | 29 (16.3) | 32 (18.0) | ||||
II | 147 (29.6) | 64 (34.4) | 65 (36.5) | 60 (33.7) | ||||
III | 290 (58.4) | 84 (45.2) | 76 (42.7) | 84 (47.2) | ||||
IV | 13 (2.6) | 2 (1.1) | 8 (4.5) | 2 (1.1) | ||||
Treatment | 12.32 | 0.000 | 2.23 | 0.135 | ||||
RT | 193 (38.8) | 100 (53.8) | 106 (59.6) | 92 (51.7) | ||||
CCRT | 304 (61.2) | 86 (46.2) | 72 (40.4) | 86 (48.3) | ||||
RT dose (Gy) | 64 (50–78) | 64 (50–70) | 0.44 | 0.660 | 64 (50–74) | 64 (50–70) | 1.552 | 0.131 |
Sex and survival for ESCC
Sex and prognostic factors for ESCC
Variates | Progression-Free Survival | Overall Survival | ||||
---|---|---|---|---|---|---|
HR(95%CI) | χ2 | p | HR(95%CI) | χ2 | p | |
gender | 0.746 (0.611–0.910) | 8.375 | 0.004 | 0.755 (0.615–0.926) | 7.275 | 0.007 |
age | 0.997 (0.988–1.006) | 0.511 | 0.475 | 0.997 (0.988–1.006) | 0.470 | 0.493 |
location | 1.162 (1.031–1.308) | 6.095 | 0.014 | 1.131 (1.003–1.275) | 4.023 | 0.045 |
T stage | 1.184 (1.029–1.362) | 5.547 | 0.019 | 1.266 (1.095–1.462) | 10.22 | 0.001 |
N stage | 1.328 (1.013–1.741) | 4.219 | 0.040 | 1.303 (0.993–1.711) | 3.640 | 0.056 |
TNM stage | 1.236 (1.014–1.506) | 4.411 | 0.036 | 1.181 (0.965–1.445) | 2.601 | 0.107 |
RT dose | 0.977 (0.954–1.001) | 3.631 | 0.057 | 0.970 (0.946–0.995) | 5.681 | 0.017 |
Treatment | 0.741 (0.621–0.884) | 11.061 | 0.001 | 0.712 (0.595–0.852) | 13.71 | 0.000 |